FGFR2 and cholangiocarcinoma: A phase III, open-label, randomized study is now being conducted to evaluate first-line pemigatinib versus gemcitabine-cisplatin in a FGFR2 rearrangement-bearing unresectable or metastatic CCA (FIGHT-302; NCT03656536).